2024-03-28T22:46:37Z
http://eprints.drcmr.dk/cgi/oai2
oai:www.drcmr.dk:34
2010-04-02T08:36:19Z
7374617475733D707562
7375626A656374733D433130:43313078313134:4331307831313478333735:433130783131347833373578353030
74797065733D61727469636C65
NORdic trial of oral Methylprednisolone as add-on therapy
to Interferon beta-1a for treatment of relapsing-remitting
Multiple Sclerosis (NORMIMS study): a randomised,
placebo-controlled trial
Soelberg Sorensen, Per
Mellgren, Svein Ivar
Svenningsson, Anders
Elovaara, Irina
Frederiksen, Jette Lautrup
Beiske, Antonie Giaever
Myhr, Kjell-Morten
Søgaard, Lise Vejby
Olsen, Inge Christoffer
Sandberg-Wollheim, Magnhild
Multiple Sclerosis
Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective, and new more effective and safe strategies are needed. Our aim was to assess the efficacy of oral methylprednisolone as an
add-on therapy to subcutaneous interferon beta-1a to reduce the yearly relapse rate in patients with relapsing-remitting
multiple sclerosis.
Methods: NORMIMS (NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment
of relapsing-remitting Multiple Sclerosis) was a randomised, placebo-controlled trial done in 29 neurology departments in Denmark, Norway, Sweden, and Finland. We enrolled outpatients with relapsing-remitting multiple sclerosis who had had at least one relapse within the previous 12 months despite subcutaneous interferon beta-1a treatment (44 microg three times per week). We randomly allocated patients by computer to add-on therapy of either 200 mg
methylprednisolone or matching placebo, both given orally on 5 consecutive days every 4 weeks for at least 96 weeks.
The primary outcome measure was mean yearly relapse rate. Primary analyses were by intention to treat. This trial is
registered, number ISRCTN16202527.
Findings: 66 patients were assigned to interferon beta and oral methylprednisolone and 64 were assigned to interferon
beta and placebo. A high proportion of patients withdrew from the study before week 96 (26% [17 of 66] on
methylprednisolone vs 17% [11 of 64] on placebo). The mean yearly relapse rate was 0.22 for methylprednisolone
compared with 0.59 for placebo (62% reduction, 95% CI 39-77%; p<0.0001). Sleep disturbance and neurological and
psychiatric symptoms were the most frequent adverse events recorded in the methylprednisolone group. Bone mineral density had not changed after 96 weeks.
Interpretation: Oral methylprednisolone given in pulses every 4 weeks as an add-on therapy to subcutaneous interferon beta-1a in patients with relapsing-remitting multiple sclerosis leads to a significant reduction in relapse rate. However, because of the small number of patients and the high dropout rate, these findings need to be corroborated in larger cohorts.
2009-06
Article
PeerReviewed
application/pdf
http://eprints.drcmr.dk/34/1/NORMIMS_Published_article_processed.pdf
Soelberg Sorensen, Per and Mellgren, Svein Ivar and Svenningsson, Anders and Elovaara, Irina and Frederiksen, Jette Lautrup and Beiske, Antonie Giaever and Myhr, Kjell-Morten and Søgaard, Lise Vejby and Olsen, Inge Christoffer and Sandberg-Wollheim, Magnhild (2009) NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurology, 8 (6). pp. 519-529.
http://eprints.drcmr.dk/34/